Welcome to the e-CCO Library!

P600: Infliximab trough levels for remission induction and long term therapy management of inflammatory bowel disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Perdigoto D., Portela F., Ferreira M., Mendes S., Freire P., Ferreira M., Lopes S., Tomé L.

Created: Wednesday, 20 February 2019, 10:36 AM
P600: Real-world clinical characteristics and therapeutic strategies in patients with moderate-to-severe Inflammatory Bowel Disease in Argentina: Data from the RISE AR study
Year: 2021
Source: ECCO'21 Virtual
Authors: Lasa, J.S.(1,2);Sambuelli, A.(3);Zubiaurre, I.(2);Correa, G.J.(4);Lubrano, P.(5);Balderramo, D.C.(6,7);Ruffinengo, O.(8);Brion, L.(9);Leonardi, D.B.(9);El-Hakeh, J.(9);Guimaraens, P.N.(9);Olivera Sendra, P.(1,5);
Created: Wednesday, 2 June 2021, 4:12 PM
P600: Serologic response to COVID-19 vaccines in IBD patients: a prospective study
Year: 2022
Source: ECCO'22
Authors: Martin ArranzPhD- MD, M.D.(1);García Ramírez, L.(2);Montero Vega, D.(3);Martín-Arraz, E.(2);Sánchez Azofra, M.(2);Poza Cordon, J.(2);Rueda Garcia, J.L.(2);Noci Belda, J.(2);Verges Martínez-Meco, T.(2);Blanco San Miguel, P.(2);Suarez Ferrer, C.(2);
Created: Friday, 11 February 2022, 3:56 PM
P600: Ustekinumab for Crohn’s disease: a nationwide real-life observational cohort study from Finland
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Eberl*1, T. Hallinen2, C-G. af Björkesten3, M. Heikkinen4, E. Hirsi5, M. Kellokumpu6, I. Koskinen7, V. Moilanen8, C. Nielsen9, H. Nuutinen10, U-M. Suhonen11, K. Utriainen12, I. Vihriälä13, E. Soini2, C. Wennerström14, R. Nissinen15, A. Borsi16, M. Koivunen15, J. Tillonen17, T. Sipponen1

Created: Friday, 22 February 2019, 9:41 AM
P601 Development and validation of dried blood spot sampling as a tool to identify the best time point to measure predictive ustekinumab serum concentrations in patients with Crohn’s disease
Year: 2020
Source:

ECCO'20 Vienna

Authors:

N. Van den Berghe1, B. Verstockt2,3, E. Vandeput2, V. Ballet2, A. Gils1, M. Ferrante2,3, S. Vermeire2,3, D. Thomas1

Created: Thursday, 30 January 2020, 10:12 AM
P601: Are Inflammatory Bowel Disease patients’ expectations met by dietetic services?
Year: 2021
Source: ECCO'21 Virtual
Authors: McCarthy, N.(1);Schultz, M.(2);Wall, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P601: Can Amitriptylin improve the quality of life in patients with Crohn's disease?
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Jigaranu A.O., Dranga M., Gavrilescu O., Popa I., Ungureanu I., Mihai C., Cijevschi-Prelipcean C.

Created: Wednesday, 20 February 2019, 10:36 AM
P601: Differential cytokine profiles and drop of faecal calprotectin for prediction of primary response to infliximab induction therapy in Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Mateos1, E. Sáez1,2, I. Moret1,3, D. Hervás4, L. Tortosa1,3, E. Cerrillo2,3, M. Iborra2,3, M. García2, P. Nos1,2,3, B. Beltrán1,2,3

Created: Friday, 22 February 2019, 9:41 AM
P601: Pneumococcal vaccination in patients with immunomediated inflammatory diseases (IMIDs) using a real-world multidisciplinary project
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Martins, A.(1);Silva, F.(2);Canelas, G.(2);Ribeiro, L.(3);Pinto, S.(3);Sarmento, A.(3);Magro, F.(4);Ferreira de Abreu, C.M.(5)*;
Created: Friday, 14 July 2023, 11:05 AM
P601: Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn’s disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study
Year: 2022
Source: ECCO'22
Authors: Bokemeyer, B.(1);Plachta-Danielzik, S.(2);di Giuseppe, R.(2);Deppe, H.(3);Mohl, W.(4);Teich, N.(5);Hoffstadt, M.(6);Schweitzer, A.(7);von der Ohe, M.(8);Gauss, A.(9);Atrya, R.(10);Krause, T.(11);Blumenstein, I.(12);Höchstödter, J.(2);Hartmann, P.(3);Schreiber, S.(13);
Created: Friday, 11 February 2022, 3:56 PM
P601: Upadacitinib improves steroid-free clinical and endoscopic endpoints in patients with Crohn’s disease: Data from the CELEST study
Year: 2018
Source: ECCO '18 Vienna
Authors:

R. Panaccione1*, R. Atreya2, M. Ferrante3, M.C. Dubinsky4, B.E. Sands4, M.T. Abreu5, F. Cataldi6, J.V. Enejosa6, Q. Zhou6, B. Huang6, A.P. Lacerda6, A.L. Pangan6

Created: Thursday, 21 February 2019, 9:14 AM
P602 Changes in emotional health and work-related outcomes in patients with moderate to severe ulcerative colitis 1 year after diagnosis: Results from the MOSAIK cohort in Korea
Year: 2020
Source:

ECCO'20 Vienna

Authors:

Y. PARK1, J.H. Cheon1, Y.S. Park2, K.C. Huh3, J.E. Shin4, J.M. Cha5, Y.S. Kim6, C.S. Eun7, S.M. Yoon8, Y.S. Park9, B.D. Ye10, B. Seo11, Y. Kim11, MOSAIK

Created: Thursday, 30 January 2020, 10:12 AM
P602: Achievement of stringent histologic and composite endpoints in subjects with moderately to severely active ulcerative colitis treated with etrasimod: a post hoc analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Magro, F.(1)*;Peyrin-Biroulet, L.(2,3);Sands, B.E.(4);Danese, S.(5);Jairath, V.(6);Goetsch, M.(7);Bhattacharjee, A.(8);Wu, J.(9);Ferreira Branquinho, D.(10);Modesto, I.(11);Feagan, B.G.(12);
Created: Friday, 14 July 2023, 11:05 AM
P602: CD-TREAT a novel dietary therapy of active Crohn’s disease using the exclusive enteral nutrition paradigm
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

V. Svolos*1, R. Hansen2, U. Z. Ijaz3, L. Gervais2, H. Duncan2, R. Tayler2, A. Barclay2, D. Flynn2, V. Garrick2, L. Curtis2, E. Buchanan2, T. Cardigan2, D. R. Gaya4, S. Milling5, R. K. Russell2, K. Gerasimidis1

Created: Friday, 22 February 2019, 9:41 AM
P602: Clinical/biochemical predictors of response to anti-TNFa therapies in a tertiary referral centre
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tighe D.*1,2, Breslin N.1, Ryan B.1, McNamara D.3

Created: Wednesday, 20 February 2019, 10:36 AM
P602: Factors associated with discontinuation of initial and subsequent tumour necrosis factor inhibitors in a large paediatric inflammatory bowel disease observational cohort
Year: 2018
Source: ECCO '18 Vienna
Authors:

J. Kaplan1,2*, C. Liu3, E. King3, J. Bass4, A. Patel5, G. Tomer6, J. Tung7, J. Pratt3, S. Chen3, T. Lissoos8, R. Colletti9, ImproveCareNow Network

Created: Thursday, 21 February 2019, 9:14 AM
P602: Tofacitinib treatment prevents post-operative recurrence of Crohn’s Disease modeled by ileocecal resection in HLA-B27 transgenic rats.
Year: 2022
Source: ECCO'22
Authors: Blondeaux, A.(1);Speca, S.(2);Valibouze, C.(3);Lambin, T.(1);Dubuquoy, C.(2);Titecat, M.(4);Genoscreen, L.(5);Neut, C.(6);Genin, M.(7);Zerbib, P.(3);Foligne, B.(6);Desreumaux, P.(1);
Created: Friday, 11 February 2022, 3:56 PM
P602: Vedolizumab subcutaneous influencing disease course in Constant-care app solution
Year: 2021
Source: ECCO'21 Virtual
Authors: Nørgaard, J.(1);Malte, R.(1);Charlotte, P.L.(1);Mette, B.(1);Eva, F.(1);Petra, W.(1);Dorit, A.(1);Lotte, S.(1);Johan, B.(1);Pia, M.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P603 Persistence of vedolizumab maintenance therapy: Findings from a Belgian registry
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Louis1, V. Muls2, P. Bossuyt3, A. Colard4, A. Nakad5, D. Baert6, F. Mana7, P. Caenepeel8, S. Vanden Branden9, S. Vermeire10, F. D’Heygere11, B. Strubbe12, A. Cremer13, J.C. Coche14, V. Setakhr15, F. Baert16, A. Vijverman17, J.L. Coenegrachts18, F. Flamme19, A. Hantson20, K. Wijnen20, E. Piters20, P. Dolin21

Created: Thursday, 30 January 2020, 10:12 AM
P603: Hospitalisation risk and reintervention after ileocolonic resection with anastomosis in patients with Crohn's disease. Results from the PRACTICROHN study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

García V.*1, Calvo M.2, Martín Arranz M.D.3, Rivero M.4, Domènech E.5, Barreiro-de Acosta M.6, García Planella E.7, Gutiérrez A.8, Romero C.9, Cea-Calvo L.9, Juliá B.9

Created: Wednesday, 20 February 2019, 10:36 AM